Abstract: TH-PO887
Safety and Effectiveness of Erythropoietin vs. Roxadustat for Anemia in Hemodialysis-Dependent Peridialytic CKD Patients: An Observational, Retrospective, Matched, Real-World Study
Session Information
- Anemia and Iron Metabolism
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Author
- Wang, Li Hua, The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China
Background
Current evidence remains elusive about the efficacy and safety of erythropoietin versus roxadustat for anemia treatment in the peridialytic period.
Methods
This study extracted longitudinal data from a metropolis-wide hospitals-based database Tianjin Healthcare and Medical Big Data Platform. Subjects with CKD stage G5 and anemia (hemoglobin <100 g/L) who had received treatment with erythropoietin or roxadustat between January 1, 2015 and December 31, 2021.
Results
Of 40,324 patients who were included and treated with erythropoietin and erythropoietin 10,000 IU were matched to 545 patients treated with roxadustat. Significant differences were observed in the rates of MACE+ events as well as cardiocerebrovascular events.
Conclusion
Erythropoietin, particularly erythropoietin 10,000 IU, improved hemoglobin response and exhibited better cardiovascular safety, as compared with roxadustat, in patients with anemia who had hemodialysis-dependent CKD in the peridialytic period.
The rates of MACE+ events within 6 and 12 months of treatment initiation, within 3 months of hemodialysis initiation and during 12 months of follow-up among patients who were treated with roxadustat, erythropoietin, or erythropoietin 10,000 IU
COX regression analysis showed that receipt of roxadustat was associated with an approximately two-fold increase in the risk of MACE+ versus erythropoietin 10,000 IU (HR=2.17, 95% CI 1.95-2.43; P<0.001).